ES2196190T3 - Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico. - Google Patents

Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.

Info

Publication number
ES2196190T3
ES2196190T3 ES96940406T ES96940406T ES2196190T3 ES 2196190 T3 ES2196190 T3 ES 2196190T3 ES 96940406 T ES96940406 T ES 96940406T ES 96940406 T ES96940406 T ES 96940406T ES 2196190 T3 ES2196190 T3 ES 2196190T3
Authority
ES
Spain
Prior art keywords
metaloproteinasas
matriciales
bifenlico
hydroxamate
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940406T
Other languages
English (en)
Inventor
Stephen W Fesik
James B Summers Jr
Steven K Davidsen
George S Sheppard
Douglas H Steinman
George M Carrera Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2196190T3 publication Critical patent/ES2196190T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA (I), O SU SAL FARMACEUTICAMENTE ACEPTABLE QUE INHIBEN LA METALOPROTEINASAS DE LA MATRIZ Y LA SECRECION DE TNF AL Y SE UTILIZAN EN EL TRATAMIENTO DE SITUACIONES DE ENFERMEDADES INFECCIOSAS. TAMBIEN SE DESCRIBEN COMPOSICIONES INHIBIDORAS DE LAS METALOPROTEINASAS DE LA MATRIZ Y DE LA SECRECION DE TNF AL Y UN PROCEDIMIENTO PARA INHIBIR LAS METALOPROTEINASAS DE LA MATRIZ Y LA SECRECION DE TNF AL .
ES96940406T 1995-11-14 1996-11-13 Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico. Expired - Lifetime ES2196190T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/555,690 US5665777A (en) 1995-11-14 1995-11-14 Biphenyl hydroxamate inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
ES2196190T3 true ES2196190T3 (es) 2003-12-16

Family

ID=24218248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940406T Expired - Lifetime ES2196190T3 (es) 1995-11-14 1996-11-13 Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.

Country Status (13)

Country Link
US (1) US5665777A (es)
EP (1) EP0874808B1 (es)
JP (1) JP2002504073A (es)
KR (1) KR19990067573A (es)
AT (1) ATE236873T1 (es)
AU (1) AU710666B2 (es)
DE (1) DE69627380T2 (es)
DK (1) DK0874808T3 (es)
ES (1) ES2196190T3 (es)
IL (1) IL123502A0 (es)
MX (1) MX9803809A (es)
PT (1) PT874808E (es)
WO (1) WO1997018188A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890114A1 (en) * 1996-03-29 1999-01-13 Lawrence Berkeley National Laboratory Enhancement of nmr and mri in the presence of hyperpolarized noble gases
DE69729007T2 (de) * 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
DK0970046T3 (da) * 1997-02-27 2004-04-13 Wyeth Corp N-Hydroxy-2-(alkyl-, aryl- eller heteroarylsulfanyl, -sulfinyl eller -sulfonyl)-3-substituerede alkyl- eller heteroaryl-amider som matrixmetalloproteinaseinhibitorer
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
ES2189207T3 (es) * 1997-07-31 2003-07-01 Abbott Lab Inhibidores de hidroxamatos inversos de metaloproteinasas matriciales.
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2000044712A1 (en) * 1999-01-27 2000-08-03 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
NZ520711A (en) * 2000-02-10 2004-03-26 Ono Pharmaceutical Co N-hydroxy-5-ethoxymethyloxy-2(S)-methyl-4(S)-(4- phenoxybenzoyl)aminopentanamide useful for treating osteoarthritis
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
JP2004359546A (ja) * 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
WO2009008905A1 (en) * 2007-02-01 2009-01-15 Panthera Biopharma, Llc. Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
CN102267923B (zh) * 2010-06-04 2015-07-15 台北医学大学 组蛋白去乙酰化酶抑制剂
US20140271465A1 (en) * 2013-03-15 2014-09-18 Mallinckrodt Llc Matrix metalloprotease (mmp) targeted agents for imaging and therapy
EP3628661A1 (en) * 2013-06-27 2020-04-01 Lg Chem, Ltd. Biaryl derivatives as gpr120 agonists
KR101829290B1 (ko) * 2014-12-24 2018-02-19 주식회사 엘지화학 Gpr120 효능제로서의 바이아릴 유도체
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
CN109820861B (zh) * 2019-03-13 2021-02-26 湖北科技学院 一种具有抗肿瘤活性的吩噻嗪类衍生物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1548641A (es) * 1967-10-26 1968-12-06
US3755603A (en) * 1970-07-01 1973-08-28 Syntex Corp Biphenylyloxyacetic acids in pharmaceutical compositions
JPS525730A (en) * 1975-07-03 1977-01-17 Nippon Shinyaku Co Ltd Process for preparation of 1,3,5-tri-substituted derivatives
JPS5762239A (en) * 1980-08-26 1982-04-15 Hisamitsu Pharmaceut Co Inc Novel phenylacetic acid derivative
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US5036157A (en) * 1986-03-11 1991-07-30 Burroughs Wellcome Co. Aryl derivatives
CA2073513A1 (en) * 1990-12-03 1992-06-04 John Robert Porter Peptidyl derivatives
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
JPH05205730A (ja) * 1992-01-29 1993-08-13 Shin Kobe Electric Mach Co Ltd 薄形鉛蓄電池
EP0634998B1 (en) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamic acid based collagenase and cytokine inhibitors
US5318964A (en) * 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
JPH07509178A (ja) * 1992-07-16 1995-10-12 シェブロン　ケミカル　カンパニー コークスで不活性化された改質触媒の低温再生法
US5310121A (en) * 1992-07-24 1994-05-10 Consilium Bulk Babcock Atlanta, Inc. Cold weather bulk stacker/reclaimer apparatus and method
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
CA2158352A1 (en) * 1993-03-16 1994-09-29 Michael John Crimmin Hydroxamic acid derivatives as metalloproteinase inhibitors
EP0715619A4 (en) * 1993-08-23 1997-03-19 Immunex Corp INHIBITORS OF TNF-ALPHA SECRETION
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production

Also Published As

Publication number Publication date
AU7729696A (en) 1997-06-05
KR19990067573A (ko) 1999-08-25
US5665777A (en) 1997-09-09
DK0874808T3 (da) 2003-08-04
ATE236873T1 (de) 2003-04-15
JP2002504073A (ja) 2002-02-05
EP0874808A1 (en) 1998-11-04
AU710666B2 (en) 1999-09-23
DE69627380D1 (en) 2003-05-15
WO1997018188A1 (en) 1997-05-22
IL123502A0 (en) 1998-09-24
EP0874808B1 (en) 2003-04-09
MX9803809A (es) 1998-09-30
DE69627380T2 (de) 2004-03-25
PT874808E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
BR9811099A (pt) Inibidores de urocinase
DK0695189T3 (da) Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
MX9308199A (es) Inhibidores de enzima.
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
NO944430L (no) 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
DK0799209T3 (da) Sulfonamider
NO942641L (no) Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
DK0705100T3 (da) Terapeutiske substituerede guanidiner
NL300091I2 (nl) Interleukine-1 remmers.
AR024138A1 (es) Inhibidores de la proliferacion celular
IL128900A0 (en) Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
PT100517A (pt) Compostos inibidores de catepsina g e de elastase para a prevencao da degenerescencia do tecido conjuntivo
NO983530L (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
BR9916255A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição em que se requer inibição de trombina e para a preparação de compostos
NO922167D0 (no) Aminodukter som korrosjonshemmere
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
PT876158E (pt) Nova utilizacao de um inibidor de eca para o tratamento de sintomas dispepticos
CO4700430A1 (es) Terapia combinada para inspeccion por vih
YU79602A (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
MX9301939A (es) Composicion farmaceutica que comprende un compuesto inhibidor de 5-ó-reductasa esteroidal.